| CAS NO: | 203640-27-1 |
| 包装 | 价格(元) |
| 10mM (in 1mL DMSO) | 电议 |
| 1mg | 电议 |
| 5mg | 电议 |
| 10mg | 电议 |
| 25mg | 电议 |
| 50mg | 电议 |
| Cas No. | 203640-27-1 |
| Canonical SMILES | O=S(N[C@@H](C(O)=O)CC1=CNC2=C1C=CC=C2)(C3=CC=C(C#CC4=CC=C(C)C=C4)S3)=O |
| 分子式 | C24H20N2O4S2 |
| 分子量 | 464.56 |
| 溶解度 | DMSO : ≥ 83.3 mg/mL (179.31 mM) |
| 储存条件 | Store at -20°C |
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
| Shipping Condition | Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request |
| 产品描述 | S-3304 is a novel matrix metalloproteinases (MMP) inhibitor specific for MMP-2 and MMP-9. S 3304 is a novel D-tryptophan derivative and a potent, orally active, noncytotoxic Matrix metalloproteinases inhibitor (MMPI). Biochemical studies show that S 3304 most potently inhibits the activities of MMP-2 and MMP-9 but does not inhibit MMP-1, MMP-3, or MMP-7 and may, therefore, lack the musculoskeletal side effects seen with nonspecific inhibitors[1]. In vivo pharmacologic studies have shown that the oral administration of S 3304, at a dose range of 20 to 200 mg/kg, inhibits angiogenesis, artificially induced in mice by the dorsal air-sac method. Similar oral doses of S 3304 result in potent inhibition of metastatic lung colonization of Lewis murine lung carcinoma injected via tail vein and liver metastasis of C-1H human colon cancer implanted into the spleen[1]. [1]. Chiappori AA, et al. A phase I pharmacokinetic and pharmacodynamic study of s-3304, a novel matrix metalloproteinase inhibitor, in patients with advanced and refractory solid tumors. Clin Cancer Res. 2007 Apr 1;13(7):2091-9. |
m.cnreagent.com